Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Payables (2016 - 2025)

Historic Payables for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $835000.0.

  • RedHill Biopharma's Payables fell 5632.85% to $835000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $835000.0, marking a year-over-year decrease of 5632.85%. This contributed to the annual value of $1.2 million for FY2024, which is 6436.85% down from last year.
  • Per RedHill Biopharma's latest filing, its Payables stood at $835000.0 for Q2 2025, which was down 5632.85% from $1.2 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Payables high stood at $119.4 million for Q4 2022, and its period low was $835000.0 during Q2 2025.
  • Its 5-year average for Payables is $14.0 million, with a median of $4.6 million in 2022.
  • In the last 5 years, RedHill Biopharma's Payables skyrocketed by 92405.69% in 2022 and then tumbled by 9725.57% in 2023.
  • Quarter analysis of 5 years shows RedHill Biopharma's Payables stood at $11.7 million in 2021, then surged by 924.06% to $119.4 million in 2022, then plummeted by 97.26% to $3.3 million in 2023, then plummeted by 64.37% to $1.2 million in 2024, then decreased by 28.51% to $835000.0 in 2025.
  • Its Payables was $835000.0 in Q2 2025, compared to $1.2 million in Q4 2024 and $1.9 million in Q2 2024.